Should You Buy Kenvue Stock After Its 30% Plunge?

Kenvue's stock experienced a significant sell-off, plunging over 30% this year, following controversial claims by President Trump and initial FDA actions suggesting a link between Tylenol (acetaminophen) and autism, which could also trigger lawsuits. While Kenvue and leading medical organizations (ACOG, AAP) have strongly refuted this link, and the FDA's subsequent communication was more nuanced, the incident adds to existing pressures from underperforming business segments that led to a CEO change and strategic review. Despite these headwinds, Kenvue's 5.1% forward dividend yield and attractive 14.8x forward earnings multiple may appeal to income-focused investors.

Analysis

Kenvue Inc. (KVUE) is navigating a period of intense pressure, with its stock declining over 30% this year due to a confluence of fundamental and external challenges. The most immediate headwind is a significant controversy, amplified by a presidential statement and initial FDA actions, suggesting a link between its flagship Tylenol product and autism. This has created a substantial legal overhang, with reports of law firms receiving over a thousand inquiries for potential lawsuits. While Kenvue, alongside reputable medical bodies like the American College of Obstetricians and Gynecologists, has strongly refuted these claims citing a lack of scientific evidence, the regulatory and litigation risks remain a primary driver of negative sentiment. This issue exacerbates pre-existing problems, including business underperformance that prompted a CEO change in July and the launch of a strategic review to simplify its product portfolio. Despite these severe challenges, the sharp sell-off has pushed Kenvue's valuation to an ostensibly attractive 14.8x forward earnings multiple and boosted its forward dividend yield to an appealing 5.1%, a key attribute for a stock that inherited a 'Dividend King' status from Johnson & Johnson.

Key Decisions for Investors

• Income-focused investors may find the 5.1% dividend yield attractive, but must weigh this against the significant headline risk from the Tylenol controversy and the potential for litigation costs to impact future capital returns.
• Given the combination of operational underperformance, a recent CEO change, and an ongoing strategic review, investors should remain cautious until management provides a clear turnaround strategy and evidence of its execution.
• Traders and investors should closely monitor developments related to the Tylenol litigation and any definitive regulatory guidance from the FDA, as these events will likely serve as major catalysts for the stock's performance in the near term.